Peregrine's Bavituximab has high success rate in animal testing

• An antibody equivalent to Peregrine's (PPHM) Bavituximab immunotherapy eradicated tumors in two-thirds of rats with non-small cell lung cancer when combined with radiation in a trial, with 100% of the animals surviving after 184 days.
• In rats that received just radiation, the survival rate was 43%, while it was 12.5% in untreated animals.
• Shares are +7.6%. (PR)